Tirzepatide — - 30mg

Tirzepatide is a synthetic peptide of significant interest in metabolic research, distinguished by its novel mechanism as a dual agonist for both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Structurally, it is a linear peptide composed of 39 amino acids. Its sequence is based on the native GIP sequence but has been modified to confer GLP-1 receptor activity. A crucial structural feature is the conjugation of a C20 fatty-diacid moiety to the lysine residue at position 20. This modification facilitates non-covalent binding to serum albumin, which dramatically extends the peptide's pharmacokinetic half-life, making it suitable for less frequent administration in longitudinal research studies.

The development of Tirzepatide represents a key advancement in the study of incretin-based therapies. While GLP-1 receptor agonists have been extensively investigated, the synergistic potential of co-activating the GIP receptor pathway is a frontier of metabolic science. The GIP receptor, historically viewed with some ambiguity in the context of type 2 diabetes models, is now being re-evaluated for its role in insulin secretion, lipid metabolism, and energy homeostasis. Tirzepatide provides researchers with a powerful tool to dissect the distinct and overlapping contributions of these two critical incretin pathways.

Its unique dual-agonist profile makes Tirzepatide a subject of intense investigation in preclinical models of obesity, type 2 diabetes, and related metabolic disorders like non-alcoholic steatohepatitis (NASH). Researchers utilize this peptide to explore fundamental questions about appetite regulation, glucose-dependent insulin secretion, energy expenditure, and lipid metabolism. By comparing its effects to those of selective GLP-1 or GIP agonists, studies can elucidate the complex interplay between these two systems. Supplied by Nexa Peptides as a high-purity lyophilized powder, our Tirzepatide is intended exclusively for in vitro and in vivo laboratory research applications. This product is not intended for human consumption.

The mechanism of action of Tirzepatide is defined by its function as a biased agonist at two distinct G-protein coupled receptors (GPCRs): the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). Its novelty lies in this dual agonism, which is believed to produce synergistic effects on metabolic regulation that are greater than those achievable with selective agonism of either receptor alone.

Upon binding to the GLP-1R, primarily located on pancreatic β-cells, neurons in the central nervous system (CNS), and other peripheral tissues, Tirzepatide initiates a signaling cascade. This activation stimulates adenylyl cyclase, leading to an increase in intracellular concentrations of cyclic adenosine monophosphate (cAMP). Elevated cAMP levels subsequently activate Protein Kinase A (PKA) and Exchange Protein Activated by cAMP 2 (EPAC2). In pancreatic β-cells, this PKA- and EPAC2-mediated pathway potentiates glucose-dependent insulin secretion, a process critical for maintaining glucose homeostasis. In the CNS, particularly the hypothalamus, GLP-1R activation is integral to the regulation of appetite, promoting satiety and reducing energy intake.

Simultaneously, Tirzepatide acts as an agonist at the GIPR. The GIPR is also highly expressed on pancreatic β-cells, as well as on adipocytes and in the brain. Similar to GLP-1R signaling, GIPR activation also elevates intracellular cAMP levels, thereby enhancing glucose-dependent insulin secretion. The GIP component of Tirzepatide's action is an area of active research; while GIP is a potent incretin, its role in energy metabolism is complex. In adipocytes, GIPR signaling is linked to lipid metabolism and may influence fat storage and nutrient handling. The combined signaling through both receptors appears to offer a more comprehensive physiological response to nutrient intake than either pathway alone.

From a molecular pharmacology perspective, Tirzepatide is considered a 'biased agonist', meaning it may preferentially activate certain downstream signaling pathways over others, potentially fine-tuning the physiological response and minimizing off-target effects studied in cellular models. The structural modification—a C20 fatty-diacid linker—is critical to its pharmacokinetics. This moiety allows Tirzepatide to reversibly bind to serum albumin, forming a depot in circulation. This sequestration protects the peptide from rapid degradation by dipeptidyl peptidase-4 (DPP-4) and clearance by the kidneys, resulting in a significantly prolonged elimination half-life. This extended duration of action is a key feature for researchers conducting long-term metabolic studies in animal models, allowing for sustained receptor engagement with less frequent administration.

Tirzepatide is a premier investigational tool for researchers focused on metabolic diseases, endocrinology, and related fields. Its primary application is in preclinical studies of obesity and type 2 diabetes, where its dual incretin receptor agonism provides a unique avenue for exploring complex physiological pathways. In animal models of obesity, such as diet-induced obese (DIO) mice and rats, Tirzepatide is studied for its effects on body weight reduction, adiposity, and food intake. These studies aim to dissect the central and peripheral mechanisms contributing to weight loss, including hypothalamic appetite signaling and changes in energy expenditure.

In the context of diabetes research, Tirzepatide is utilized in models like the Zucker diabetic fatty (ZDF) rat or streptozotocin-induced diabetic models to investigate its impact on glycemic control. Research objectives often include quantifying its ability to improve glucose tolerance, enhance glucose-dependent insulin secretion from isolated pancreatic islets, and increase insulin sensitivity in peripheral tissues like muscle, liver, and adipose tissue. Comparative studies are frequently designed to benchmark the effects of Tirzepatide against selective GLP-1 receptor agonists, thereby isolating the specific contributions of GIP receptor co-activation to overall metabolic improvement.

Beyond glycemic control and weight, the research applications of Tirzepatide extend to associated metabolic comorbidities. Its effects are being investigated in preclinical models of non-alcoholic fatty liver disease (NAFLD) and its more severe form, non-alcoholic steatohepatitis (NASH). In these studies, researchers assess its potential to reduce hepatic steatosis (fat accumulation), inflammation, and fibrosis by analyzing liver histology and relevant biochemical markers. This line of inquiry explores the interplay between incretin signaling and hepatic lipid metabolism.

Cardiovascular research represents another important application. Given the strong link between metabolic syndrome and cardiovascular disease, studies in relevant animal models examine Tirzepatide's effects on lipid profiles (e.g., triglycerides, cholesterol), blood pressure, and markers of systemic inflammation and endothelial function. These investigations seek to understand whether the metabolic benefits observed with Tirzepatide translate to improvements in cardiovascular risk parameters in a laboratory setting. All such applications are strictly for non-human, in vitro or in vivo research to advance fundamental scientific understanding. For Research Use Only.